Requires health benefit plans to cover biomarker testing when supported by medical and scientific evidence.
Mississippi SB2694 mandates that health benefit plans, health insurers, nonprofit health service plans, and health maintenance organizations provide coverage for biomarker testing for diagnosis, treatment, management, or monitoring of an enrollee's disease or condition. The testing must be supported by medical and scientific evidence, including FDA-approved tests, CMS determinations, or clinical practice guidelines. Insurers must provide specific written justification for any denied claims for biomarker testing supported by such evidence.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.